Our group aims to deliver the highest quality translational and clinical research within both investigator- and commercial-led clinical trials with a focus on relieving the disease burden of MS to patients and their carers.
Multiple sclerosis (MS) is the most common cause of progressive disability in young adults in the Western world. It is characterised by inflammatory demyelinating CNS plaques. However, the major pathological substrate for disability is the associated axonal and neuronal damage. Current therapies predominantly target the immune system and the development of effective neuroprotective therapies to prevent disability and the methodologies to assess them cost-effectively represents a significant unmet need in MS.
A major focus of our group is upon translational research examining neuroprotective therapies in both acute and progressive forms of Multiple Sclerosis using a combination of advanced imaging, functional and clinical outcomes.
In addition, we engage in a large portfolio of collaborative clinical trial research as part of a national and international network of MS researchers and Pharmaceutical companies.